• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, May 13, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

RANZCO outlines stance on blue light

by Myles Hume
January 29, 2020
in Lenses, Local, News, Products
Reading Time: 3 mins read
A A
Share on FacebookShare on Twitter

A newly published RANZCO position paper has suggested there is little to no evidence blue light blocking spectacles improve visual performance or protect macular health, however screen-emitted blue light may interrupt circadian rhythms.

The college has released a six-page statement outlining its official opinion on the impact of blue light and digital screens on ocular health as part of its efforts to improve public awareness on the issue. The paper, approved by the RANZCO board in mid-2019 before being published online this month, addresses issues related to retinal protection, visual comfort and the impact on sleep.

It comes as Australia’s ophthalmic community works to clarify the benefits and myths surrounding blue light filters. Previously, Optometry Australia announced it is also reviewing literature in order to guide eyecare professionals in their recommendations.

According to RANZCO, no evidence exists to suggest normal environmental exposure, including that from digital screen technology, causes damage to eyesight and macular health. It also concluded filtering out blue light from screens is not necessary in normal use.

“Animal studies have generally used intensities and durations of light exposure that would rarely occur in normal life although some experimental evidence is emerging that repeated exposure at lower intensities may be more harmful than a single brief exposure,” the position statement said.

The paper cited a 2017 study by Moon et al that showed exposure of cultured retinal pigment epithelium cells to light equivalent to that emitted from mobile display devices caused free radical production and reduced cell viability.

“However, in life these cells are not directly exposed to blue light and extrapolation to real life exposure in humans may not be possible.”

In relation to devices, some authors have measured the blue light output to inform risk to the eye. “[And they] found that computer screens and smart phones have a very low level blue light radiance being about <0.5% of the luminance level that the International Commission on Non-Ionizing Radiation Protection consider safe.”

Sleeping patterns

According to RANZCO, it has become increasingly apparent that screen-emitted blue light can have an effect on circadian rhythms. This is due to specific cells in the retina that respond best to blue light, contributing to signals that control the biological clock.

“Blue light is beneficial during daylight hours because it boosts attention, reaction times, and mood but is disruptive at night,” the paper said.

“Melatonin is a neurohormone that regulates sleep. Experiments comparing the effects of exposure to blue light with exposure to green light show that blue light suppresses melatonin for about twice as long as the green light and shifts circadian rhythms by twice as much (3 hours vs. 1.5 hours).

“Studies have also shown that blue light in the range of 470–490 nm is more effective compared to monochromatic light of 555 nm in phase-shifting the human circadian clock.”

The college recommended there maybe benefits to reducing screen time in the evening or using night-time screen settings a few hours before bedtime.

With regards to reducing the symptoms of eyestrain, patients should take regular breaks, occasionally focus on distant objects and ensure spectacles, if worn, are appropriate for the task.

The merits and disadvantages of blue light blocking IOLs was beyond the scope of this position paper but may form part of future statements. RANZCO will undertake its next blue light review in July 2022.

Tags: biological clockblocking lensesblue lightcircadian rhythmseyestrainintraocular lensIOLsocular healthOptometry Australiaposition paperRANZCOReviewspectacles

Related Posts

There were 1,156 allegations to Ahpra of ‘boundary violations’ in 2023-24. 
Image: Pormezz/Shutterstock.com.

Ahpra reforms: Sexual misconduct on register permanently

by Staff Writer
May 13, 2025

Optometrists, ophthalmologists and other registered Australian practitioners proven to have committed sexual misconduct will have this information permanently published against...

Each year, Vision Australia helps between 80 and 100 people with blindness and low vision into employment.  Image: Vision Australia.

Vision Australia – working to give people a future and a ‘fair go’

by Rob Mitchell
May 12, 2025

A diagnosis of permanent vision loss is not the end. At Vision Australia it’s the start of a new journey...

American professional golfer Phil Mickelson has co-founded a performance-nutrition company. Image: Shutterstock.com.

Golfing great Mickelson debuts ‘gummies’ for better vision

by Staff Writer
May 12, 2025

A great golf swing won't be too good to you if you can't see where the ball ends up. Amercian...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited